LT3312195T - Nebaigtinės osteogenezės gydymo būdai - Google Patents

Nebaigtinės osteogenezės gydymo būdai

Info

Publication number: LT3312195T
Authority: LT; Lithuania
Prior art keywords: osteogenesis; infinite; treatment; methods; infinite osteogenesis
Prior art date: 2013-03-20

Application number

LTEP17206987.4T

Other languages

English (en)

Inventor

Brendan Lee

Kuber Sampath

Original Assignee

Genzyme Corporation

Baylor College Of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-20

Filing date

2014-03-20

Publication date

2020-01-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3312195(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-20 Application filed by Genzyme Corporation, Baylor College Of Medicine filed Critical Genzyme Corporation

2020-01-10 Publication of LT3312195T publication Critical patent/LT3312195T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Inorganic Chemistry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LTEP17206987.4T 2013-03-20 2014-03-20 Nebaigtinės osteogenezės gydymo būdai LT3312195T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201361803647P	2013-03-20	2013-03-20
US201361875399P	2013-09-09	2013-09-09
US201361883151P	2013-09-26	2013-09-26

Publications (1)

Publication Number	Publication Date
LT3312195T true LT3312195T (lt)	2020-01-10

Family

ID=50483613

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP17206987.4T LT3312195T (lt)	2013-03-20	2014-03-20	Nebaigtinės osteogenezės gydymo būdai
LTEP14717386.8T LT2976359T (lt)	2013-03-20	2014-03-20	Nebaigtinės osteogenezės gydymo būdai

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP14717386.8T LT2976359T (lt)	2013-03-20	2014-03-20	Nebaigtinės osteogenezės gydymo būdai

Country Status (26)

Country	Link
US (4)	US9598486B2 (lt)
EP (3)	EP3312195B1 (lt)
JP (3)	JP6483086B2 (lt)
KR (1)	KR102257138B1 (lt)
CN (2)	CN105229028B (lt)
AU (1)	AU2014235933B2 (lt)
CA (1)	CA2907422C (lt)
CL (1)	CL2015002801A1 (lt)
DK (2)	DK3312195T3 (lt)
EA (1)	EA032327B1 (lt)
ES (2)	ES2700238T5 (lt)
HR (2)	HRP20181939T4 (lt)
HU (1)	HUE046702T2 (lt)
IL (2)	IL241461B (lt)
LT (2)	LT3312195T (lt)
MX (2)	MX389759B (lt)
MY (1)	MY172324A (lt)
PH (2)	PH12015501864A1 (lt)
PL (2)	PL3312195T3 (lt)
PT (2)	PT3312195T (lt)
RS (2)	RS58188B2 (lt)
SG (2)	SG11201506683XA (lt)
SI (2)	SI2976359T2 (lt)
TW (1)	TWI629995B (lt)
UY (1)	UY35493A (lt)
WO (1)	WO2014153435A1 (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE046702T2 (hu) *	2013-03-20	2020-03-30	Genzyme Corp	Eljárások üvegcsontbetegség kezelésére
TWI726870B (zh)	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) *	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
JP2019533003A (ja) *	2016-08-11	2019-11-14	プレシセラ，インコーポレイテッド	ＴＧＦ−βアンタゴニストコンジュゲート
CN106755395B (zh) *	2016-12-16	2020-05-12	山东第一医科大学(山东省医学科学院)	Xi型成骨不全致病基因fkbp10的突变位点及其应用
EP3571227A1 (en) *	2017-01-20	2019-11-27	Sanofi	Anti-tgf-beta antibodies and their use
TWI788321B (zh) *	2017-01-20	2023-01-01	美商健臻公司	骨靶向抗體
TW202506185A (zh) *	2017-01-20	2025-02-16	法商賽諾菲公司	抗TGF-β抗體及其用途
AR110904A1 (es) *	2017-01-20	2019-05-15	Sanofi Sa	ANTICUERPOS ANTI-TGF-b Y SU USO
WO2019113123A1 (en) *	2017-12-04	2019-06-13	Precithera, Inc.	TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
TW202019962A (zh)	2018-07-10	2020-06-01	法商賽諾菲公司	標靶CD38及TGF-β的組合療法
MY204234A (en)	2018-08-27	2024-08-16	Regeneron Pharma	Use of raman spectroscopy in downstream purification
CN110916855A (zh) *	2018-09-20	2020-03-27	天津正天医疗器械有限公司	一种仿生多孔椎间植入物及其制造方法
KR20230112629A (ko) *	2020-10-23	2023-07-27	에이치큐 한	종양괴사인자-알파 및 형질전환성장인자-베타의 이작용성 길항제 및 이의 용도
IL308175A (en) *	2021-05-07	2023-12-01	Baylor College Medicine	Treatment of moderate to severe defective bone formation
CN113501879B (zh) *	2021-06-30	2022-09-06	拜盖特生物科技(上海)有限公司	一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
US20230144192A1 (en) *	2021-11-01	2023-05-11	Genzyme Corporation	Treatment of osteogenesis imperfecta
JP2026502549A (ja) *	2023-01-13	2026-01-23	シャンハイ・カイジン・バイオテクノロジー，リミテッド	多重特異性ポリペプチド複合体
CN120290673A (zh) *	2025-04-02	2025-07-11	湖北省农业科学院农产品加工与核农技术研究所	一种抗光老化胶原多肽的制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL6716836A (lt) *	1967-12-11	1969-06-13
US7368111B2 (en) *	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
AU1525700A (en) *	1998-11-19	2000-06-05	Board Of Trustees Of The University Of Arkansas, The	Increasing bone strength with selected bisphosphonates
US20040009535A1 (en) *	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
DE69933044T3 (de) *	1998-11-27	2016-11-24	Ucb Pharma, S.A.	Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
CA2308532C (en) *	1999-05-12	2005-11-29	Gador S.A.	Use of bisphosphonates for the treatment of osteogenesis imperfecta
US6659982B2 (en)	2000-05-08	2003-12-09	Sterling Medivations, Inc.	Micro infusion drug delivery device
US6629949B1 (en)	2000-05-08	2003-10-07	Sterling Medivations, Inc.	Micro infusion drug delivery device
WO2006086469A2 (en)	2005-02-08	2006-08-17	Genzyme Corporation	Antibodies to tgfbeta
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
JP2009521496A (ja) *	2005-12-23	2009-06-04	イーライリリーアンドカンパニー	ＴＧＦ−β結合組成物
WO2008022182A1 (en) *	2006-08-16	2008-02-21	The Uab Research Foundation	Methods for promoting coupling between bone formation and resorption
ES2756725T3 (es) *	2007-02-09	2020-04-27	Acceleron Pharma Inc	Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
US20100204053A1 (en) *	2007-04-26	2010-08-12	President And Fellows Of Harvard College	Assays for the identification of compounds that modulate bone formation and mineralization
TWI489993B (zh) *	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101932603A (zh) *	2008-01-15	2010-12-29	卡罗拜奥斯制药公司	使用gm-csf拮抗剂治疗骨质流失病症的方法
US20120294868A1 (en) *	2009-04-24	2012-11-22	Edwards James R	Anti-tgf-beta induction of bone cell function and bone growth
HUE046702T2 (hu) *	2013-03-20	2020-03-30	Genzyme Corp	Eljárások üvegcsontbetegség kezelésére

2014
- 2014-03-20 HU HUE17206987A patent/HUE046702T2/hu unknown
- 2014-03-20 PT PT172069874T patent/PT3312195T/pt unknown
- 2014-03-20 EP EP17206987.4A patent/EP3312195B1/en active Active
- 2014-03-20 UY UY0001035493A patent/UY35493A/es not_active Application Discontinuation
- 2014-03-20 DK DK17206987.4T patent/DK3312195T3/da active
- 2014-03-20 PT PT14717386T patent/PT2976359T/pt unknown
- 2014-03-20 HR HRP20181939TT patent/HRP20181939T4/hr unknown
- 2014-03-20 RS RS20181438A patent/RS58188B2/sr unknown
- 2014-03-20 WO PCT/US2014/031279 patent/WO2014153435A1/en not_active Ceased
- 2014-03-20 SI SI201430985T patent/SI2976359T2/sl unknown
- 2014-03-20 MY MYPI2015702733A patent/MY172324A/en unknown
- 2014-03-20 KR KR1020157028130A patent/KR102257138B1/ko active Active
- 2014-03-20 PL PL17206987T patent/PL3312195T3/pl unknown
- 2014-03-20 DK DK14717386.8T patent/DK2976359T4/da active
- 2014-03-20 SG SG11201506683XA patent/SG11201506683XA/en unknown
- 2014-03-20 SI SI201431435T patent/SI3312195T1/sl unknown
- 2014-03-20 PL PL14717386.8T patent/PL2976359T5/pl unknown
- 2014-03-20 SG SG10201701985YA patent/SG10201701985YA/en unknown
- 2014-03-20 CN CN201480028990.8A patent/CN105229028B/zh active Active
- 2014-03-20 ES ES14717386T patent/ES2700238T5/es active Active
- 2014-03-20 EA EA201591843A patent/EA032327B1/ru not_active IP Right Cessation
- 2014-03-20 US US14/772,708 patent/US9598486B2/en active Active
- 2014-03-20 CN CN201910988588.9A patent/CN111000997A/zh active Pending
- 2014-03-20 LT LTEP17206987.4T patent/LT3312195T/lt unknown
- 2014-03-20 AU AU2014235933A patent/AU2014235933B2/en active Active
- 2014-03-20 LT LTEP14717386.8T patent/LT2976359T/lt unknown
- 2014-03-20 ES ES17206987T patent/ES2763869T3/es active Active
- 2014-03-20 TW TW103110468A patent/TWI629995B/zh active
- 2014-03-20 RS RS20191624A patent/RS59673B1/sr unknown
- 2014-03-20 CA CA2907422A patent/CA2907422C/en active Active
- 2014-03-20 JP JP2016504355A patent/JP6483086B2/ja active Active
- 2014-03-20 EP EP14717386.8A patent/EP2976359B2/en active Active
- 2014-03-20 MX MX2019009122A patent/MX389759B/es unknown
- 2014-03-20 EP EP19194235.8A patent/EP3640260A1/en not_active Withdrawn
- 2014-03-20 MX MX2015013402A patent/MX369360B/es active IP Right Grant
2015
- 2015-08-25 PH PH12015501864A patent/PH12015501864A1/en unknown
- 2015-09-10 IL IL241461A patent/IL241461B/en unknown
- 2015-09-17 CL CL2015002801A patent/CL2015002801A1/es unknown
2017
- 2017-02-08 US US15/427,920 patent/US10377819B2/en active Active
2019
- 2019-02-06 PH PH12019500261A patent/PH12019500261B1/en unknown
- 2019-02-12 JP JP2019022397A patent/JP6677837B2/ja active Active
- 2019-07-01 US US16/459,023 patent/US11230595B2/en active Active
- 2019-12-17 HR HRP20192277TT patent/HRP20192277T1/hr unknown
2020
- 2020-03-12 JP JP2020042524A patent/JP7016113B2/ja active Active
2021
- 2021-11-08 IL IL287915A patent/IL287915A/en unknown
- 2021-12-09 US US17/547,069 patent/US12365725B2/en active Active

Also Published As

Publication number	Publication date
KR102257138B1 (ko)	2021-05-26
DK2976359T3 (da)	2019-01-02
HRP20181939T1 (hr)	2019-01-25
CN105229028A (zh)	2016-01-06
EP2976359B2 (en)	2022-03-23
US20220195025A1 (en)	2022-06-23
SI2976359T1 (sl)	2019-03-29
IL287915A (en)	2022-01-01
EP3312195A1 (en)	2018-04-25
JP2016519093A (ja)	2016-06-30
HRP20192277T1 (hr)	2020-03-06
WO2014153435A1 (en)	2014-09-25
SG10201701985YA (en)	2017-04-27
ES2763869T3 (es)	2020-06-01
TW201524515A (zh)	2015-07-01
EP2976359B1 (en)	2018-08-29
HK1213576A1 (en)	2016-07-08
PT3312195T (pt)	2019-12-23
PL2976359T5 (pl)	2022-07-18
ES2700238T5 (es)	2022-05-20
MY172324A (en)	2019-11-21
EA032327B1 (ru)	2019-05-31
JP7016113B2 (ja)	2022-02-04
CN111000997A (zh)	2020-04-14
MX2015013402A (es)	2016-01-08
SI2976359T2 (sl)	2022-05-31
SG11201506683XA (en)	2015-09-29
DK3312195T3 (da)	2020-01-06
AU2014235933A1 (en)	2015-10-01
DK2976359T4 (da)	2022-06-13
EP3312195B1 (en)	2019-10-09
EP2976359A1 (en)	2016-01-27
US20160031979A1 (en)	2016-02-04
TWI629995B (zh)	2018-07-21
UY35493A (es)	2014-11-28
IL241461A0 (en)	2015-11-30
PL2976359T3 (pl)	2019-03-29
MX369360B (es)	2019-11-06
EP3640260A1 (en)	2020-04-22
US10377819B2 (en)	2019-08-13
US11230595B2 (en)	2022-01-25
US9598486B2 (en)	2017-03-21
JP6483086B2 (ja)	2019-03-13
IL241461B (en)	2021-12-01
MX389759B (es)	2025-03-20
JP2020109110A (ja)	2020-07-16
KR20150132262A (ko)	2015-11-25
PH12019500261B1 (en)	2021-03-26
RS58188B1 (sr)	2019-03-29
PH12015501864B1 (en)	2015-12-07
RS58188B2 (sr)	2022-06-30
CL2015002801A1 (es)	2016-08-12
US12365725B2 (en)	2025-07-22
JP2019089826A (ja)	2019-06-13
ES2700238T3 (es)	2019-02-14
CA2907422A1 (en)	2014-09-25
PL3312195T3 (pl)	2020-04-30
AU2014235933B2 (en)	2019-01-24
SI3312195T1 (sl)	2020-02-28
US20170247439A1 (en)	2017-08-31
EA201591843A1 (ru)	2016-01-29
BR112015023905A2 (pt)	2017-10-24
CA2907422C (en)	2021-08-31
HK1253717A1 (en)	2019-06-28
MX2019009122A (es)	2019-09-16
HUE046702T2 (hu)	2020-03-30
PT2976359T (pt)	2018-12-05
NZ712353A (en)	2021-04-30
LT2976359T (lt)	2018-12-27
CN105229028B (zh)	2019-11-08
US20190389943A1 (en)	2019-12-26
HRP20181939T4 (hr)	2022-05-13
PH12015501864A1 (en)	2015-12-07
JP6677837B2 (ja)	2020-04-08
PH12019500261A1 (en)	2020-07-20
RS59673B1 (sr)	2020-01-31

Publication	Publication Date	Title
IL280908B (en)	2022-01-01	Combination therapy with neoantigen vaccine
LT3312195T (lt)	2020-01-10	Nebaigtinės osteogenezės gydymo būdai
IL268987B (en)	2021-01-31	System for glaucoma treatment
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
EP3620203C0 (en)	2024-11-13	VASCULAR TREATMENT DEVICES
IL240388A0 (en)	2015-09-24	Methods of treating melanoma
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
DK3021838T3 (da)	2020-08-24	Behandling af fedme
PL3542798T3 (pl)	2025-09-08	Aceklidyna do zastosowania w leczeniu starczowzroczności
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
LT2981255T (lt)	2022-11-25	Empagliflozino terapiniai panaudojimo būdai
DK3076976T3 (da)	2020-12-07	Fremgangsmåder til behandling af cancer
HRP20190101T1 (hr)	2019-03-08	Terapeutske uporabe empagliflozina
PT3626270T (pt)	2024-01-11	Tratamento de doenças cardiovasculares
PT2953948T (pt)	2017-12-12	Antagonistas de integrina fluorada
DK2961378T3 (da)	2019-11-25	Fremgangsmåder til behandlingen af mitochondrisk sygdom
EP2982331A4 (en)	2016-11-02	Treatment tool
LT2991633T (lt)	2019-07-25	Terapija bakteriografu
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
IL254825A0 (en)	2017-12-31	Methods of treatment with taselisib
EP2839068A4 (en)	2015-11-25	Clothes treatment apparatus
PL2948137T3 (pl)	2019-02-28	Sposoby leczenia zwłóknienia i nowotworów
EP2999799A4 (en)	2016-12-28	METHOD FOR TREATING CARCINOMA
DK2964248T3 (da)	2019-08-26	Behandling af og profylakse for stråledermatitis
EP2988738A4 (en)	2016-11-09	THERAPEUTIC INDICATIONS OF KINASE INHIBITORS